CARDS: The Collaborative Atorvastatin Diabetes Study

1
CARDS The Collaborative Atorvastatin Diabetes
Study

• Purpose
• To assess the effectiveness of 10 mg
  atorvastatin daily in the primary prevention of
  cardiovascular disease in patients with type 2
  diabetes, but without high concentrations of
  LDL-cholesterol
• Reference
• Colhoun HM, Betteridge PN, Hitman GA et al.
  Primary prevention of cardiovascular disease with
  atorvastatin in the Collaborative Atorvastatin
  Diabetes Study (CARDS) multicentre randomised
  placebo-controlled trial. Lancet
  2004264685696.

2
CARDS The Collaborative Atorvastatin Diabetes
Study - TRIAL DESIGN -

• Design
• Multicenter, multinational, randomized,
  double-blind, parallel group
• Patients
• 2838 patients aged 40-75 yrs with type 2
  diabetes mellitus and at least one of
  hypertension, retinopathy, albuminuria, smoking.
  Patients with history of MI, angina, coronary
  vascular surgery, cerebrovascular accident or
  severe peripheral vascular disease ineligible
• Follow up and primary endpoint
• Primary endpoint acute coronary event, coronary
  revascularization, or stroke. Median 3.9 years
  follow-up
• Treatment
• Atorvastatin 10 mg per day or placebo

3
CARDS The Collaborative Atorvastatin Diabetes
Study - TRIAL DESIGN continued-
Baseline characteristics
4
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS -

• Compared with placebo, patients receiving 10 mg
  atorvastatin daily showed a 37 reduction in
  major cardiovascular events from 9.0 to 5.8 (p
  0.001)
• There was a favourable trend in the atorvastatin
  group with regard to all cause mortality, acute
  coronary events, coronary revascularization, and
  stroke
• Adverse event rate similar in atorvastatin and
  placebo groups.
• No cases of rhabdomyolysis.

5
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -

6
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
Breakdown of primary endpoint by treatment
7
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
8
CARDS The Collaborative Atorvastatin Diabetes
Study - SUMMARY -

• Atorvastatin (10 mg, once daily) is safe and
  effective in reducing the risk of cardiovascular
  events, including stroke, in patients with type 2
  diabetes
• There was a favourable trend in the atorvastatin
  group with regard to all cause mortality, major
  coronary events, coronary revascularization, and
  stroke